Related Experiment Video
Updated: Jul 5, 2026
10:05
Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC (Crosslinking of Small Molecules to Isolate Chromatin)
Published on: January 20, 2016
Steric Determinants of Pt/DNA Interactions and Anticancer Activity
T W Hambley1, S J Berners-Price, M S Davies
1School of Chemistry University of Sydney NSW 2006 Australia.
Metal-Based Drugs
|May 14, 2008
Summary
Platinum drug interactions with DNA are key to anticancer activity. Structural features, like steric bulk, significantly influence Pt/DNA binding, though this doesn't always correlate with drug efficacy.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Molecular Biology
Background:
- Platinum-based drugs are crucial in cancer chemotherapy.
- Understanding platinum-DNA interactions is vital for developing new anticancer agents.
- Structural features dictate drug efficacy.
Purpose of the Study:
- To investigate structural determinants of platinum-DNA interactions.
- To correlate these interactions with the anticancer activity of platinum drugs.
- To elucidate the role of steric and hydrogen bonding in Pt/DNA adduct formation.
Main Methods:
- Two-dimensional NMR spectroscopy ([(1)H, (15)N]-HSQC) to study reactions of cisplatin with oligonucleotides.
- Synthesis and analysis of sterically bulky and optically active platinum complexes.
- In vitro cytotoxicity assays.
Main Results:
- Differential binding rates of cisplatin to ApG and GpA sites observed.
- Outer-sphere interactions influence reaction rates, unlike cis-[Pt(NH(3))(2)(OH(2))(2)](2+).
- Steric interactions are major factors in Pt(II) binding to DNA; hydrogen bonds play a lesser role.
- Adduct profiles do not consistently predict in vitro cytotoxic activity.
Conclusions:
- Structural features, particularly steric bulk, significantly impact platinum drug binding to DNA.
- The relationship between DNA adduct formation and cytotoxicity is complex and not always predictable.
- Further research is needed to fully understand platinum drug mechanisms and optimize anticancer therapies.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:10Radical Reactivity: Steric Effects
The presence of electron-donating, electron-withdrawing, or conjugating groups adjacent to a radical center, imparts electronic stabilization to the radicals. Examples of such electronically-stabilized radicals are triphenylmethyl, tetramethylpiperidine‐N‐oxide, and 2,2‐diphenyl‐1‐picrylhydrazyl. These radicals are remarkably stable and are known as persistent radicals. Some of the persistent radicals can even be isolated and purified.
Along with electronic factors, steric factors also account...
Along with electronic factors, steric factors also account...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...